within Pharmacolibrary.Drugs.ATC.R;

model R03AC18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.43,
    Cl             = 14.466666666666667,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 2.36,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Indacaterol is a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is inhaled once daily as a bronchodilator and is approved for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, after single and multiple-dose inhalation.</p><h4>References</h4><ol><li><p>Vaidya, S, et al., &amp; Tillmann, HC (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. <i>Pulmonary pharmacology &amp; therapeutics</i> 64 101964–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2020.101964&quot;>10.1016/j.pupt.2020.101964</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33035700/&quot;>https://pubmed.ncbi.nlm.nih.gov/33035700</a></p></li><li><p>Ren, S, et al., &amp; Zhao, R (2017). Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 55(2) 147–155. DOI:<a href=&quot;https://doi.org/10.5414/CP202640&quot;>10.5414/CP202640</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27841152/&quot;>https://pubmed.ncbi.nlm.nih.gov/27841152</a></p></li><li><p>Vaidya, SS, et al., &amp; Kaiser, G (2016). Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 5(4) 285–295. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.245&quot;>10.1002/cpdd.245</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27310329/&quot;>https://pubmed.ncbi.nlm.nih.gov/27310329</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AC18;
